Literature DB >> 30870726

Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites.

Brinda Rao Korivi1, Silvana Faria2, Asran Aly3, Jia Sun4, Madhavi Patnana5, Corey T Jensen6, Nicolaus Wagner-Bartak7, Priya R Bhosale8.   

Abstract

OBJECTIVE: We assessed differences in primary sites and spread patterns of the intestinal and diffuse subtypes of gastric carcinoma. We also compared survival outcomes based on spread patterns.
MATERIALS AND METHODS: For this retrospective IRB-approved study, our institutional imaging database was mined for patients with gastric cancer. We included 99 treatment-naïve patients. Patient demographics, pathologic data, tumor classification, primary tumor site, and metastasis sites were recorded. Pearson's chi-squared test was used to correlate tumor pathology with metastatic sites. Kaplan-Meier survival curves were compared between baseline metastatic types. A heat map was created based on the relative frequencies of metastatic sites for each primary tumor site.
RESULTS: Of the 99 patients, 66 patients had intestinal and 33 had diffuse gastric carcinoma. The intestinal subtype was significantly associated with hepatic metastases (p < 0.001). Diffuse subtype was associated with peritoneal metastases, including omental metastases (p < 0.006), gastrosplenic ligament involvement (p < 0.004), and mesocolonic implants (p < 0.008). Patients with primary gastric tumors occurring at the greater curvature had longer overall survival than those with primary sites at the antrum, GE junction and lesser curvature (p = 0.0015). Patients with peritoneal metastases had a significantly shorter overall survival than patients without peritoneal metastases (p < 0.001). Patients without mesocolon, gastrohepatic ligament, and gastrosplenic ligament involvement had a better survival (p = 0.005, p = 0.0002, and p = 0.0005, respectively). Presence of hepatic metastases had no effect on survival (p = 0.16).
CONCLUSION: Recognizing distinctive spread patterns for intestinal versus diffuse gastric carcinoma can aid radiologists in diagnosis and guide clinical management.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diffuse subtype; Gastric carcinoma; Intestinal subtype

Mesh:

Year:  2019        PMID: 30870726     DOI: 10.1016/j.clinimag.2019.03.002

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  4 in total

1.  Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer.

Authors:  Wei Li; Xu Zhang; Fenglei Wu; Ying Zhou; Zengtao Bao; Haining Li; Ping Zheng; Shaolin Zhao
Journal:  Cell Death Dis       Date:  2019-12-04       Impact factor: 8.469

2.  Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer.

Authors:  Seo Ree Kim; Kabsoo Shin; Jae Myung Park; Han Hong Lee; Kyo Yong Song; Sung Hak Lee; Bohyun Kim; Sang-Yeob Kim; Junyoung Seo; Jeong-Oh Kim; Sang-Young Roh; In-Ho Kim
Journal:  J Gastric Cancer       Date:  2020-12-17       Impact factor: 3.720

3.  Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.

Authors:  Sung-Hwa Sohn; Hee Jung Sul; Bum Jun Kim; Hyeong Su Kim; Dae Young Zang
Journal:  Int J Mol Sci       Date:  2021-12-30       Impact factor: 5.923

4.  Copy number alterations and epithelial‑mesenchymal transition genes in diffuse and intestinal gastric cancers in Mexican patients.

Authors:  Violeta Larios-Serrato; José-Darío Martínez-Ezquerro; Hilda-Alicia Valdez-Salazar; Javier Torres; Margarita Camorlinga-Ponce; Patricia Piña-Sánchez; Martha-Eugenia Ruiz-Tachiquín
Journal:  Mol Med Rep       Date:  2022-04-01       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.